Form 8-K · Current Report · Filed 2025-10-27
Revvity Reports Third Quarter 2025 Financial Results and Announces $1B Share Repurchase
Revvity, Inc. reported financial results for the third quarter of 2025, showing a 2% reported revenue growth and 1% organic growth. The company earned GAAP EPS of $0.40 and Adjusted EPS from continuing operations of $1.18. Revvity reaffirmed its full-year 2025 organic growth guidance and raised its adjusted EPS guidance. Additionally, the company announced a new $1 billion share repurchase program. Further financial details and guidance updates are provided in the press release.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-25-000032
- CIK
- 0000031791
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$98.89
Next session
-2.5%
Since filing
+48.4%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.